Lasofoxifene: A new type of selective estrogen receptor modulator for the treatment of osteoporosis

Drugs of Today

Volumn 42, Issue 6, 2006, Pages 355-367

  Gennari, Luigi ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYTAMOXIFEN; 6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ARZOXIFENE; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CLOMIFENE; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DROLOXIFENE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ETHINYLESTRADIOL; IDOXIFENE; LASOFOXIFENE; PARATHYROID HORMONE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE;

AGING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BONE DENSITY; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DYSTOCIA; FRAGILITY FRACTURE; GLUCURONIDATION; HALF LIFE TIME; HORMONE RESPONSE; HOT FLUSH; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEG CRAMP; NONHUMAN; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; THROMBOEMBOLISM; TUMOR GROWTH; UROGENITAL TRACT DISEASE; UTERUS CANCER; VASODILATATION;

ANIMALS; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PYRROLIDINES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TETRAHYDRONAPHTHALENES;

EID: 33746261241     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2006.42.6.973583     Document Type: Review

References (67)

1. Osteoporosis Prevention, Diagnosis, and Therapy Consensus Statement 2000. JAMA 2001, 285: 785-95.
2. Center, J.R., Nguyen, T.V., Schneider, D., Sambrook, P.N., Eisman, J.A. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 1999, 353: 878-82.
3. Melton, L.J., Atkinson, E.J., Cooper, C., O'Fallon, W.M., Riggs, B.L. Vertebral fractures predict subsequent fracture. Osteoporos Int 1999, 10: 214-21.
4. Riggs, B.L., Melton, L.J. III. The prevention and treatment of osteoporosis. New Engl J Med 1992, 327: 620-7.
5. Melton, L.J., Thamer, M., Ray, N.F. et al. Fractures attributable to osteoporosis: Report from the national osteoporosis foundation. J Bone Miner Res 1997, 12: 16-23.
6. Cummings, S.R., Black, D.M., Nevitt, M.C. et al. Bone density at various sites for prediction of hip fractures. Lancet 1993, 341: 72-5.
7. Barrett-Connor, E. The economic and human costs of osteoporotic fracture. Am J Med 1995, 98: 3S-8S.
8. Cooper, C., Campion, G., Melton, L.J. III. Hip fractures in the elderly: A world-wide projection. Osteoporos Int 1992, 2: 285-9.
9. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical report series, WHO, Geneva 1994.
10. Hui, S.L., Slemenda, C.W., Carey, M.A., Johnston, C.C. Choosing between predictors of fractures. J Bone Miner Res 1995, 10: 1816-22.
11. Cummings, S.R., Black, D.M., Nevitt, M.C. et al. Appendicular bone density and age predict hip fracture in women: The Study of Osteoporotic Fractures Research Group. JAMA 1990, 263: 665-8.
12. Black, D.M., Cummings, S.R., Genant, H.K., Nevitt, M.C., Palermo, L., Browner, W. Axial and appendicular bone density predict fractures in older women. J Bone Miner Res 1992, 7: 633-8.
13. Chlebowski, R.T., Wactawski-Wende, J., Ritenbaugh, C. et al.; Women's Health Initiative Investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004, 350: 991-1004.
14. Manson, J.E., Hsia, J., Johnson, K.C. et al.; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003, 349: 523-34.
15. Vassilopoulou-Sellin, R. Breast cancer and hormonal replacement therapy. Ann N Y Acad Sci 2003, 997: 341-50.
16. HRT: What are women (and their doctors) to do? Lancet 2004, 364: 2069-70.
17. Lopez, F.J. New approaches to the treatment of osteoporosis. Curr Opin Chem Biol 2000, 4: 383-93.
18. Cho, C.H., Nuttall, M.E. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs 2001, 6: 137-54.
19. Morello, K.C., Wurz, G.T., DeGregorio, M.W. SERMs: Current status and future trends. Crit Rev Oncol Hematol 2002, 43: 63-76.
20. Weinstein, R.S., Parfitt, A.M., Marcus, R., Greenwald, M., Crans, G., Muchmore, D.B. Effects of raloxifene, hormone replacement therapy, and placebo on bone turnover in postmenopausal women. Osteoporos Int 2003, 14: 814-22.
21. Prestwood, K.M., Gunness, M., Muchmore, D.B., Lu, Y., Wong, M., Raisz, L.G. A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women. J Clin Endocrinol Metab 2000, 85: 2197-202.
22. Rosati, R.L., Da Silva Jardine, P., Cameron, K.O. Discovery and preclinical pharmacology of a novel, potent, nonsteroidal estrogen receptor agonist/antagonist, CP-336156, a diaryltetrahydronaphthalene. J Med Chem 1998, 41: 2928-31.
23. Cameron, K. Discovery of CP-336156, a potent estrogen agonist. 219th ACS Nat Meeting, San Francisco 2000 (MEDI 326).
24. Yang, X., Reinhold, A.R., Rosati, R.L., Liu, K.K. Enzyme-catalyzed asymmetric deacylation for the preparation of lasofoxifene (CP-336156), a selective estrogen receptor modulator. Organic Letters 2000, 2: 4025-7.
25. Ke, H.Z., Paralkar, V.M., Grasser, W.A. Effects of CP-336,156, a new, nonsteroidal estrogen agonist/antagonist, on bone, serum cholesterol, uterus and body composition in rat models. Endocrinology 1998, 139: 2068-76.
26. Bryant, H.U., Glasebrook, A.L., Yang, N.N., Sato, M. A pharmacological review of raloxifene. J Bone Miner Metab 1996, 14: 1-9.
27. Eppenberger, U., Wosikowski, K., Kung, W. Pharmacologic and biologic properties of droloxifene, a new antiestrogen. Am J Clin Oncol 1991, 14: S5-S14.
28. Harris, H., Bapat, A.R., Gonder, D.S., Frail, D.E. The ligand binding profiles of estrogen receptors α and β are species dependent. Steroids 2002, 67: 379-84.
29. Bindal, R.D., Katzenellenbogen, J.A. 1,2-Dyaril-3,4-dihydronaphthalenes: Photofluorogenic ligands for the estrogen receptor. J Steroid Biochem 1985, 23: 929-37.
30. Gennari, L. Lasofoxifene (Pfizer). Curr Opin Investig Drugs 2005, 6: 1067-78.
31. Gardner, M., Nishizawa, Y., Wei, G., Dogolo, L., Calcagni, A. A single-dose pharmacokinetic study of lasofoxifene in Japanese and Caucasian postmenopausal women J Bone Miner Res 2004, 19 (S1): Abst. M469.
32. Fountaine, R. et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of daily lasofoxifene (LASO) in Japanese (J) and Caucasian (C) postmenopausal (PM) women. Clin Pharmacol Ther 2005, 77: Abst. PII-124.
33. Moller, R., Fisher, J., Taylor, A., Kolluri, S., Gardner, M. Effect of food on the pharmacokinetics of lasofoxifene in healthy postmenopausal women. J Bone Miner Res 2004, 19 (S1): Abst. SU487.
34. Gardner, M. et al. Clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women. J Clin Pharmacol 2006, 46: 52.
35. Bramson, C., Ouellet, D., Roman, D., Randinitis, E., Gardner, M.J. A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment. J Clin Pharmacol 2006, 46: 29.
36. Gardner, M.J. et al. Pharmacokinetics (PK) of lasofoxifene (LASO), a next-generation selective estrogen receptor modulator. Clin Pharmacol Ther 2005, 77: Abst. PII-34.
37. Ozolins, T.R.S., Gupta, U. Embryo/fetal toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in rats and rabbits. Birth Defects Res B Dev Reprod Toxicol 2004, 71: 161-70.
38. Chesworth, R., Zawistoski, M.P., Lefker, B.A. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorg Med Chem Lett 2004, 14: 2729-33.
39. Bramlett, K.S., Burris, T.P. Target specificity of selective estrogen receptor modulators within human endometrial cancer cells. J Steroid Biochem Mol Biol 2003, 86: 27-34.
40. Ke, H.Z., Qi, H., Chidsey-Frink, K.L., Crawford, D.D., Yu, L., Thompson, D.D. Effects of different dose regimens of lasofoxifene (CP-336,156) in preventing bone loss in ovariectomized rats. J Bone Miner Res 2000, 15: S1-S310.
41. Ke, H.Z., Foley, G.L., Simmons, H.A., Shen, V., Thompson, D.D. Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 2004, 145: 1996-2005.
42. Kharode, Y.P., Green, P.D., Marzolf, J.T. et al. Comparison of the effects of bazedoxifene, raloxifene, lasofoxifene and risedronate, co-treatment on h-PTH-induced reversal of established osteopenia in ovariectomized rats. J Bone Miner Res 2003, S1: Abst. SU387.
43. Ke, H.Z., Qi, H., Crawford, D.T., Chidshey-Frink, K.L., Simmons, H.A., Thompson, D.D. Lasofoxifene (CP-336-156), a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinology 2000, 141: 1338-44.
44. Ke, H.Z., Qi, H., Chidsey-Frink, K.L. et al. Lasofoxifene (CP-336,156) protects against the age-related decreases in bone mass and bone strength and the age-related increases in fat body mass and serum cholesterol in aged male rats. J Bone Min Res 2000, 15: S1 Abst. M245.
45. Ke, H.Z., Oi, H., Chidsey-Frink, K.L., Crawford, D.T., Thompson, D.D. Lasofoxifene (CP-336,156) protects against the age-related changes in bone mass, bone strength and total serum cholesterol in intact aged male rats. J Bone Miner Res 2001, 16: 765-73.
46. Ke, H.Z., Chidsey-Frink, K.L., Crawford, D.T., Qi, H., Simmons, A., Thompson, D.D. Co-treatment of lasofoxifene (CP-336,156) and estrogen inhibits estrogen's effect in the uterus but maintains the bone-protective effects in ovariectomized rats. J Bone Miner Res 2000, 15: S1 Abst. SA411.
47. Helvering, L.M., Adrian, M.D., Geiser, A.G. et al. Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in rat uterus. Biol Reprod 2005, 72: 830-41.
48. Cohen, L.A., Pittman, B., Wang, C.X., Aliaga, C., Yu, L., Moyer, J.D. LAS, a novel selective estrogen receptor modulator with chemopreventive and therapeutic activity in the N-nitroso-N-methylurea-induced rat mammary tumor model. Cancer Res 2001, 61: 8683-8.
49. Ciriza, I., Carrero, P., Azcoitia, I., Lundeen, S.G., Garcia-Segura, L.M. Selective estrogen receptor modulators protect hippocampal neurons from kainic acid excitoxicity: Differences with the effect of estradiol. J Neurobiology 2004, 61: 209-21.
50. Cappon, G.D., Horimoto, M., Hurtt, M.E. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in male rats. Birth Defects Res B Dev Reprod Toxicol 2004, 71: 142-9.
51. Terry, K.K., Cappon, G.D., Hurtt, M.E., Tassinari, M.S., Gupta, U. Reproductive toxicity assessment of lasofoxifene, a selective estrogen receptor modulator (SERM), in female rats. Birth Defects Res B Dev Reprod Toxicol 2004, 71: 150-60.
52. Weisenburger, W.P., Hagler, A.R., Tassinari, M.S. Pre- and postnatal development studies of lasofoxifene, a selective estrogen receptor modulator (SERM), in Sprague-Dawley rats. Birth Defects Res B Dev Reprod Toxicol 2004, 71: 171-84.
53. Cohen, I.R., Wierda, D., Griffey, K.I., Fisher, L.F., Francis, P.C. The selective estrogen receptor modulator, raloxifene: A segment II/III delivery study in rats. Reprod Toxicol 1998, 12: 271-88.
54. Lee, A., Radecki, D., Wolter, K. et al. Lasofoxifene phase 2 and phase 3 clinical trial design and strategy. J Bone Miner Res 2005, 20: S1 Abst. M384.
55. Day, W., Martel, J., Lee, A. Lasofoxifene phase 2 dose response analysis in postmenopausal women. J Bone Miner Res 2005, 20: S1 Abst. M385.
56. Moffett, A.H., Ettinger, M., Bolognese, M. et al. Lasofoxifene, a next-generation SERM, is effective in preventing loss of BMD and reducing LDL-C in postmenopausal women. J Bone Miner Res 2004, 19: S1 Abst. SA426.
57. McClung, M., Siris, E., Cummings, S. et al. Lasofoxifene increased BMD of the spine and hip and decreased bone turnover markers in postmenopausal women with low or normal BMD. J Bone Miner Res 2005, 20: S1 Abst. F429.
58. Ligand earns milestone from Pfizer as lasofoxifene enters phase II for osteoporosis; first of three late-stage SERM products advancing prospects of future royalties. Ligand Pharmaceuticals International Inc. press release, September 26, 2000.
59. McClung, M., Omizo, M., Weiss, S. et al. Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmenopausal women. J Bone Miner Res 2004, 19: S1 Abst. SA424.
60. Portman, D.J., Moffett, A.M., Bachman, G.A., West, C., Symons, J. Lasofoxifene, a selective estrogen receptor modulator, improves objective measures of vaginal atrophy. Obst Gynecol 2004, 103: 25S-26S.
61. McClung, M., Portman, D., Emkey, R. et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J Bone Miner Res 2004, 19: S1 Abst. SA423.
62. Davidson, M., Moffett, A., Welty, F. et al. Extra-skeletal effects of lasofoxifene on postmenopausal women. J Bone Miner Res 2005, 20: S1 Abst. SA428.
63. Bernstein, L., Deapen, D., Cerhan, J.R. et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999, 91: 1654-62.
64. Sadowski, K.K., Shott, S., Brubaker, L. A comparison of women with primary and recurrent pelvic prolapse. Am J Obstet Gynecol 1999, 180: 1415-8.
65. Morello, K., Wurtz, G.T., De Gregorio, M.W. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003, 42: 500-7.
66. Guidelines Preclinical Evaluation Clin Trials Osteoporosis. World Health Organization, Geneva 1998, VI 68.
67. Curry, T.E., Osteen, K.G. The matrix metalloproteinase system: Changes, regulation, and impact throughout the ovarian and uterine reproductive cycle. Endocr Rev 2003, 24: 428-65.